Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at firstname.lastname@example.org
Neuro News Roundup: Hot Topics and Key Insights From Women in Medicine
In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.
Clinical Provider Survey Reveals Varied Levels of Comfort for Migraine Treatment During Pregnancy
Majority of women’s healthcare providers reported in a survey feeling either somewhat or very comfortable with recommending or continuing acute treatments for pregnant patients with migraine.
REGENXBIO's Clinical Trial for Duchenne Therapy RGX-202 Begins Patient Recruitment
Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.
Novartis Discontinues Huntington Disease Program Following Phase 2b Study
Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.
Whole Brain Volume Loss, Higher Thalamic and Hippocampal Atrophy Rate Identified in MOGAD
A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.
Relapse Patterns and Disease Phenotype Correlate With Treatment Change in NMOSD
Results from the CIRCLES cohort demonstrated a significant association in relapse patterns and disease phenotype for patients with NMOSD who change treatment.
Gamma Frequency Sensory Stimulation as a Potential Therapy for Alzheimer Disease
Li-Huei Tsai, PhD, director, the Picower Institute for Learning and Memory at Massachusetts Institute of Technology, discussed research results using gamma frequency sensory stimulation in Alzheimer disease.
5 Pending FDA Decisions in Neurology to Look for in 2023
Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.
Older Patients With Onset NMOSD Experience More Frequent Transverse Myelitis
According to a medical records analysis, patients with late onset NMOSD experience transverse myelitis more frequently at disease onset in comparison with early onset NMOSD.
Assessing Stroke Risk With Algorithms and Modeling Health Discrimination
Michael Pencina, PhD, vice dean for data science at Duke University School of Medicine spoke about assessing the differences in stroke risk with Americans using algorithms.
Motivations Behind Use of Keystroke Dynamics in Multiple Sclerosis
Michelle Chen, PhD, a neuropsychologist at Rutgers University, talked about the motivations behind her most recent published study on incorporating keystroke dynamics in MS cognition.
FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845
The FDA lifted its clinical hold on Astellas Pharma's FORTIS trial for evaluating AT845 in adults with late-onset Pompe disease.
FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data
In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.
Inconsistency Identified in Techniques Used to Assess Subjective Cognitive Complaints in Parkinson Disease
A systematic review revealed inconsistencies in the literature for assessing subjective cognitive complaints in cognitively normal patients with Parkinson disease.
CT103A Displays Manageable Safety Profile in Relapsed, Refractory AQP4-IgG Seropositive NMOSD
Results from on ongoing phase 1 trial showed a favorable safety profile with CT103A in patients with NMOSD.
Management of Alzheimer Disease With Lecanemab
Sharon Cohen, MD, FRCPC, provided an investigator perspective on the use of lecanemab for patients with Alzheimer disease and what the clinician community can take away from the trials.
Alterations in Gylmphatic Activity Not Significant in Different Narcolepsy Types, Correlated With PSG Parameters
Glymphatic function demonstrated no significant difference in patients with type 1 and type 2 narcolepsy in comparison with healthy controls.
Significance of a Potential Traditional Approval of Lecanemab
Sharon Cohen, MD, FRCPC, offered her insight on the significance of the lecanemab approval and what it means for patients with Alzheimer disease.
Clinical Outlook on ND0612 in Parkinson’s Disease
Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.
Rare, Fatal Case of Neuromyelitis Optica Post–COVID-19 Vaccination Explained
A rare case of neuromyelitis optica was reported with a woman aged in her 70s from Iran who experienced neurological symptoms after COVID-19 vaccination.
Adolescents and Parents Prefer Receiving Medical Information at Diagnosis of Narcolepsy
A questionnaire showed that adolescents with narcolepsy and parents prefer to receive details on narcolepsy at the time of diagnosis from a healthcare provider.
CSF Glucocerebrosidase Activity Associated With Risk of Dementia in Parkinson Disease
A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.
Rare Seronegative NMOSD Case Identified
A study reported a rare case of seronegative NMOSD with a middle-aged man in Nepal who did not improve in clinical status and performance after given treatment.
Acupuncture Shows Effectiveness for Anxiety in Patients With Parkinson Disease
After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.
FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review
UCB’s rozanolixizumab received priority review on its biologic license application by FDA and expects feedback during the second quarter of 2023.
LX9211’s Impact on Sleep Interference and Neuropathic Pain
Anand Patel, MD, CPI, chief medical officer at Conquest Research, spoke about the findings from the phase 2 RELIEF-DPN-1 trial assessing LX9211 in sleep health.
Case Report Highlights Diagnosis of Antibody-Positive NMOSD After Second COVID-19 Vaccination
A rare case report illustrated an 80-year-old man with aquaporin-4 antibody-positive NMOSD following a second dose of the Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine.
Investigation Report on Biogen’s Alzheimer Drug Aducanumab Finds Flaws in Review Process, Pricing
A recent congressional investigation report on Biogen’s aducanumab and the FDA’s approval process recommended Biogen to fulfill their responsibility for individuals who rely on their treatments.
Visual Field Defect Higher in Patients with NMOSD-ON Than Idiopathic ON
Results from a prospective study demonstrated a higher visual field defect in patients with neuromyelitis optica spectrum disorder-optic neuritis compared with those who had idiopathic optic neuritis.
Prioritizing Sleep Health From a Public Health Standpoint
The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.
2 Clarke Drive Cranbury, NJ 08512